Dong Li^*1, Fei-fan Sun^*1, Dan Wang^*1, Tao Wang^*, Jing-jing Peng^*, Jian-Qiong Feng^*, Hua Li^*, Chao Wang^†, Dai-jun Zhou^*, Hong Luo^*, Zeng-qiang Fu^*, Tao Zhang^*

Oncology Research, Vol.28, No.5, pp. 467-481, 2020, DOI:10.3727/096504020X15925659763817

Abstract Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of cancers. However, the expression, function, and regulation of PD-L1 in sorafenib-resistant hepatoma cells remain unclear. In this study, we reported that PD-L1 was overexpressed in sorafenib-resistant hepatoma cells, and shRNA-mediated PD-L1 depletion attenuated drug resistance and suppressed the migration,… More >

Dong Li^*1, Fei-fan Sun^*1, Dan Wang^*1,Tao Wang^*, Jing-jing Peng^*, Jian-Qiong Feng^*, Hua Li^*, Chao Wang^†, Dai-jun Zhou^*, Hong Luo^*, Zeng-qiang Fu^*, Tao Zhang^*

Oncology Research, Vol.28, No.7-8, pp. 827-828, 2020, DOI:10.3727/096504021X16280937554409

Abstract Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of cancers. However, the expression, function, and regulation of PD-L1 in sorafenib-resistant hepatoma cells remain unclear. In this study, we reported that PD-L1 was overexpressed in sorafenib-resistant hepatoma cells, and shRNA-mediated PD-L1 depletion attenuated drug resistance and suppressed the migration,… More >